SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending amid excitement surrounding a new partnership with Perplexity AI, which includes a $400 million deal and integration of AI search into Snapchat. The community is discussing the potential for this deal, combined with a stock buyback program, to signal a turnaround and re-rate the stock, especially given Snap's large user base and AI initiatives. Some traders are anticipating a short squeeze and upgrades from analysts.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as investors debate the impact of AI on its language learning platform. While some fear free AI translation apps could disrupt their business, others argue that language learning is irreplaceable and see long-term value, especially with growing revenue and user numbers. Community discussions also revolve around the recent stock drop following earnings, with some viewing it as a manipulation and buying opportunity.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors anticipate potential news, possibly a partnership or buyout, around the upcoming earnings call. Community discussions revolve around the possibility of a short squeeze, with some expressing frustration over the stock's performance and management's communication. Speculation about a potential deal with AstraZeneca is circulating, fueled by their aligned earnings call dates and a past real estate transaction.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors assess the impact of recent earnings and guidance, with debates focusing on long-term profitability and growth potential. Community members are weighing the company's AI integration and potential for a short squeeze against concerns about valuation and lock-up periods. The stock's performance relative to peers and broader market trends is also a key talking point.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as the community debates its potential amid discussions of buybacks and token unlocks scheduled for February. Some investors express concerns about competitor influence, particularly from $BNB and $ASTER, while others champion $AVNT as a Coinbase-backed project with a live buyback dashboard and locked developer tokens. Traders are watching key price levels, anticipating volatility and potential for a short squeeze.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending amid speculation around potential partnerships and recent insider buying, with community members closely watching resistance levels. SoftBank's earlier interest in a takeover is resurfacing in discussions. Despite sector tailwinds, the stock's YTD performance remains a key talking point.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as analysts weigh in following recent earnings and amid some volatility related to data privacy concerns and short-seller reports. The community is actively discussing price targets, potential SEC investigations, and the company's growth prospects in the mobile gaming and e-commerce sectors, with some anticipating a continued climb while others remain cautious.

BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.

BGM Group Ltd. - Ordinary Shares - Class A

BGM Group Ltd

BGM is trending amid community discussions about its potential in AI and robotics, with some viewing it as an undervalued play in the sector. Community members are closely watching for a breakout, citing technical indicators and recent acquisitions as potential catalysts. Some traders believe BGM's strategic shift and consolidation in the AI landscape positions it for significant growth.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty ($ELF) is trending due to a recent analyst downgrade from Piper Sandler, citing concerns about growth and profitability despite the Rhode brand acquisition, causing a sharp stock drop and sparking debate among investors about its valuation. Some see the dip as a buying opportunity, pointing to the brand's Gen Z appeal and potential tariff benefits, while others express skepticism about its growth prospects and caution against investing in makeup companies amid technological advancements.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings, with many expecting strong results driven by growth, distribution, and the Alani Nu acquisition. The community is closely watching for a potential breakout and discussing the possibility of a run-up leading to earnings. Some traders believe the stock is being manipulated, presenting a buying opportunity before a potential surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates

Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for...

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire GAITHERSBURG, Md., Oct. 30, 2025...

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novavax (NVAX) closed at $8.52, marking a -2.07% move from the previous day.

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

Novavax (NVAX) closed the most recent trading day at $8.46, moving 1.51% from the previous trading session.

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with...

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAXNovavax Inc